55 related articles for article (PubMed ID: 36735530)
1. Characteristics and Outcomes of Cancer Patients With Venous Thromboembolic Events After Treatment With Immune Checkpoint Inhibitors.
Dutra B; Garcia-Rodriguez V; Garcia R; Szafron D; Abraham F; Khurana S; Lockhart J; Amin R; Wang Y; Thomas A
Am J Clin Oncol; 2023 Mar; 46(3):94-100. PubMed ID: 36735530
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
[TBL] [Abstract][Full Text] [Related]
3. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Molina GE; Zubiri L; Cohen JV; Durbin SM; Petrillo L; Allen IM; Murciano-Goroff YR; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Mooradian MJ; Bardia A; Mai M; Sullivan RJ; Semenov YR; Villani AC; Reynolds KL
Oncologist; 2021 Jun; 26(6):514-522. PubMed ID: 33655682
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Immune-Related Venous Thromboembolism and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Li H; Li H; Tang L; Niu H; He L; Luo Q
Clin Appl Thromb Hemost; 2023; 29():10760296231206799. PubMed ID: 37844585
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
Fahey CC; Gracie TJ; Johnson DB
Expert Rev Anticancer Ther; 2023 Jul; 23(7):673-683. PubMed ID: 37194222
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K; Gaziano JM; Fillmore NR
Am J Hematol; 2023 Aug; 98(8):1214-1222. PubMed ID: 37161855
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
8. Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors.
Jeay M; Carbonnel F; Robert C; Mussini C; Bellanger C; Meyer A
Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102311. PubMed ID: 38430989
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Schmitt C; Hoefsmit EP; Fangmeier T; Kramer N; Kabakci C; Vera González J; Versluis JM; Compter A; Harrer T; Mijočević H; Schubert S; Hundsberger T; Menzies AM; Scolyer RA; Long GV; French LE; Blank CU; Heinzerling LM
Cancer Immunol Immunother; 2023 Nov; 72(11):3475-3489. PubMed ID: 37606856
[TBL] [Abstract][Full Text] [Related]
10. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
von Itzstein MS; Yang Y; Wang Y; Hsiehchen D; Sheffield TY; Fattah F; Popat V; Ahmed M; Homsi J; Dowell JE; Rashdan S; Lohrey J; Hammers HJ; Hughes RS; Wang T; Xie Y; Gerber DE
Front Immunol; 2024; 15():1351739. PubMed ID: 38690281
[TBL] [Abstract][Full Text] [Related]
11. Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure.
Pizuorno Machado A; Shatila M; Liu C; Lu Y; Altan M; Glitza Oliva IC; Zhao D; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5989-5998. PubMed ID: 36611109
[TBL] [Abstract][Full Text] [Related]
12. Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors.
Sperling G; Shatila M; Varatharajalu K; Lu Y; Altan M; Zhou Y; Zhao D; De Toni EN; Török HP; Schneider BJ; Khan A; Thomas AS; Zhang HC; Shafi MA; Wang Y
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17597-17605. PubMed ID: 37917197
[TBL] [Abstract][Full Text] [Related]
13. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
[TBL] [Abstract][Full Text] [Related]
14. Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors.
Yang K; Li J; Sun Z; Bai C; Zhao L
Clin Exp Med; 2023 Nov; 23(7):3907-3918. PubMed ID: 37016065
[TBL] [Abstract][Full Text] [Related]
15. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.
Gikandi A; Chi SN; Yeo KK; O'Neill AF; Shulman DS; DuBois SG; Collins NB
Cancer Med; 2024 Apr; 13(8):e7154. PubMed ID: 38629258
[TBL] [Abstract][Full Text] [Related]
16. Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department.
Pini F; Grigoriu B; Lieveke A; Meert AP
Emerg Med J; 2024 Apr; ():. PubMed ID: 38688713
[TBL] [Abstract][Full Text] [Related]
17. Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events.
Wesevich A; He G; Tomczyk G; Reid P
J Cancer Educ; 2023 Oct; 38(5):1486-1492. PubMed ID: 37022615
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Immune Checkpoint Inhibitors in Cancer Patients With Autoimmune Disease: A Retrospective Cohort Study.
Raghavan AA; Goutam S; Musto G; Geirnaert M; Ye C; O'Neil LJ; Graham J
J Immunother; 2023 Nov; ():. PubMed ID: 37937529
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation.
Bjursten S; Zhao Z; Al Remawi H; Studahl M; Pandita A; Simrén J; Zetterberg H; Lundell AC; Rudin A; Ny L; Levin M
EBioMedicine; 2024 Feb; 100():104955. PubMed ID: 38171113
[TBL] [Abstract][Full Text] [Related]
20. Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study.
Zhu J; Chen Y; Zhang Y; Wang W; Wang Y; Lu Z; Zhang Y; Lei H; Li D; Long B; Liu H
Cancer Med; 2023 Sep; 12(18):18531-18541. PubMed ID: 37584246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
